hexamethylene bisacetamide has been researched along with Myelodysplastic Syndromes in 5 studies
N,N'-diacetyl-1,6-diaminohexane: chemical name obtained from Acta Biol Hung 1990;41(1-3):199-208
Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hexamethylene bisacetamide (HMBA) is a potent inducer of differentiation of a number of transformed cell lines in vitro." | 6.67 | Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. ( Andreeff, M; Ervin, T; Kufe, D; Marks, PA; Michaeli, J; Rifkind, RA; Sogoloff, H; Stone, R; Tong, WP; Young, CW, 1992) |
| "The efficacy of hexamethylene bisacetamide (HMBA), a potent polar-planar solvent which is capable of differentiating leukemias and solid tumors in vitro at clinically achievable concentrations, was studied in 16 patients with severe myelodysplastic syndromes (MDS)." | 3.68 | Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations. ( Auerbach, M; Conley, BA; Donehower, RC; Jones, RJ; Rowinsky, EK; Spivak, JL, 1992) |
| "Hexamethylene bisacetamide (HMBA) is a potent inducer of differentiation of a number of transformed cell lines in vitro." | 2.67 | Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. ( Andreeff, M; Ervin, T; Kufe, D; Marks, PA; Michaeli, J; Rifkind, RA; Sogoloff, H; Stone, R; Tong, WP; Young, CW, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Santini, V | 1 |
| Ferrini, PR | 1 |
| Kizaki, M | 1 |
| Koeffler, HP | 1 |
| Andreeff, M | 1 |
| Stone, R | 1 |
| Michaeli, J | 1 |
| Young, CW | 1 |
| Tong, WP | 1 |
| Sogoloff, H | 1 |
| Ervin, T | 1 |
| Kufe, D | 1 |
| Rifkind, RA | 1 |
| Marks, PA | 1 |
| Rowinsky, EK | 2 |
| Conley, BA | 1 |
| Jones, RJ | 2 |
| Spivak, JL | 2 |
| Auerbach, M | 1 |
| Donehower, RC | 2 |
| Burke, PJ | 1 |
| Griffin, CA | 1 |
2 reviews available for hexamethylene bisacetamide and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Differentiation therapy of myelodysplastic syndromes: fact or fiction?
Topics: Acetamides; Amifostine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Argin | 1998 |
Differentiation-inducing agents in the treatment of myelodysplastic syndromes.
Topics: Acetamides; Azacitidine; Calcitriol; Drug Therapy, Combination; Humans; Interferons; Myelodysplastic | 1992 |
1 trial available for hexamethylene bisacetamide and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent.
Topics: Acetamides; Adolescent; Adult; Aged; Bone Marrow; Cell Differentiation; Hematopoietic Stem Cells; Hu | 1992 |
2 other studies available for hexamethylene bisacetamide and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations.
Topics: Acetamides; Adult; Aged; Algorithms; Cell Division; Depression, Chemical; Drug Administration Schedu | 1992 |
Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitors.
Topics: Acetamides; Adult; Aged; Bone Marrow; Cell Differentiation; Cell Transformation, Neoplastic; Colony- | 1990 |